【摘要】 [目的]探讨华蟾素胶囊联合XELOX方案治疗晚期胃癌临床疗效及对患者免疫状态和血清CEA、CA19-9、MMP-14水平的影响。[方法]回顾性分析我院2014年12月~2017年6月就诊收治的108例晚期胃癌患者临床资料,并根据治疗方式的不同分为观察组、对照组(各54例)。对照组给予单独XELOX方案化疗治疗,观察组在对照组基础上联合华蟾素胶囊治疗,比较2组患者的近期疗效、不良反应情况及治疗前后的外周血T淋巴细胞亚群、血清CEA、CA19-9、MMP-14水平变化。[结果]观察组的近期总有效率(RR:64.81%)、肿瘤控制率(DSR:85.19%)均分别高于对照组(38.89%、64.81%)(P<0.05)。治疗后2组患者CD4~+、CD4~+/CD8~+、CD3~+水平均较治疗前上升,且观察组较对照组上升明显(P<0.05),CD8~+均较治疗前下降,且观察组较对照组下降明显(P<0.05),治疗后2组患者血清CEA、CA19-9、MMP-14水平均较治疗前降低,且观察组较对照组降低明显(P<0.05),观察组胃肠道不良反应发生率低于对照组(P<0.05)。[结论]华蟾素胶囊联合XELOX方案治疗晚期胃癌患者临床疗效显著,可有效的改善患者免疫状态,降低血清CEA、CA19-9、MMP-14水平及消化道不良反应。更多还原

【Abstract】 [Objective]To investigate the clinical efficacy of cinobufacin capsules combined with XELOX chemotherapy in treatment of advanced gastric cancer and its effects on immune status and serum levels of CEA,CA19-9 and MMP-14.[Methods]The clinical data of 108 patients with advanced gastric cancer treated in our hospital from December 2014 to June 2017 were analyzed retrospectively.And patients were divided into observation group and control group(54 cases each)according to different treatment methods.The control group was given XELOX chemotherapy alone,the observation group received cinobufacini capsules combined with XELOX chemotherapy.The short term curative effect,adverse reactions and changes of peripheral blood T lymphocyte subsets,serum CEA,CA19-9 and MMP-14 levels before and after treatmentwere compared between the two groups.[Results]The total effective rate(RR:64.81%)and tumor control rate(DSR:85.19%)in the observation group were significantly higher than those in the control group(38.89%,64.81%,P<0.05).After treatment,the levels of CD4~+,CD4~+/CD8~+and CD3~+in both groups increased compared with that before treatment,and the increase level in observation group was more significant than that in control group(P<0.05).CD8~+in both groups decreased compared with that before treatment,and the decreased level in observation group was more significant than that in control group(P<0.05).The levels of serum CEA,CA19-9 and MMP-14 in the two groups after treatment were lower than those before treatment,and the decreased level in observation group was more significant than that in control group(P<0.05).The incidence of gastrointestinal adverse reactions in the observation group was lower than that in the control group(P<0.05).[Conclusion]The cinobufagin capsule combined with XELOX chemotherapy is effective to improve the immune status and reduce the levels of serum CEA,CA19-9 and MMP-14 and gastrointestinal adverse reactions in the treatment of advanced gastric cancer.更多还原